Puerarin (Daidzein-8-C-Glucoside · Cardiovascular · Cerebrovascular)

Compound	Puerarin (Daidzein-8-C-β-D-Glucoside; Kudzu Root Isoflavone; 8-C-Glucosyldaidzein)
Chemical class	Polyphenol — Isoflavone C-Glycoside (daidzein with C-C glucose bond at C-8; acid-hydrolysis resistant)
CAS	3681-99-0
Primary source	Pueraria lobata (Kudzu root — primary species), Pueraria tuberosa (Indian Kudzu), Pueraria mirifica
Key applications	Cardiovascular; cerebrovascular; neuroprotective; alcohol metabolism; menopausal support
Claim strength	Moderate to High
Typical form	Puerarin 98% Powder (Kudzu; high-purity isolate); Puerarin 40% Powder (Standardized Kudzu Extract)
Buy from Herbuno	Puerarin 98% Powder (Kudzu) | High-Purity Isolate | Pueraria lobata → Puerarin 40% Powder (Kudzu Extract) | Standardized Pueraria lobata →

Name origin: Puerarin is named after Pueraria — the Kudzu genus — and is the primary isoflavone of Kudzu root, accounting for up to 2–3% of dry root weight. It is the C-glucoside of daidzein at C-8 — the glucose is attached via a direct C-C bond (unlike daidzin's O-glucoside bond), making it resistant to acid hydrolysis and most gut glucosidases. This C-glycosidic stability is the key pharmacokinetic property distinguishing puerarin from daidzin. Traditional use: Pueraria lobata (Ge Gen, Kudzu root) has been used in TCM for over 2,000 years — first documented in the Shen Nong Ben Cao Jing (Divine Farmer's Materia Medica, ~200 CE) for fever, stiff neck, gastrointestinal disorders, and cardiovascular conditions. The Shang Han Lun (Treatise on Cold Damage) includes Ge Gen Huang Qin Huang Lian Tang — a classical formula using Kudzu for enteritis and diarrhoea with cardiovascular co-morbidities. Puerarin was identified as Ge Gen's primary bioactive in 20th-century Chinese phytochemistry research. Research trajectory: Puerarin has advanced to pharmaceutical status in China — Puerarin Injection (intravenous) is a CFDA-approved drug used in Chinese hospitals for acute myocardial infarction, unstable angina, and ischaemic cerebrovascular disease. This pharmaceutical clinical evidence base places puerarin among the best-clinically-evidenced isoflavones globally, second only to genistein for bone density in terms of RCT depth. Commercial source: Puerarin 98% Powder and Puerarin 40% Powder (both standardised Pueraria lobata isolate preparations) are available from Herbuno — among the most precisely standardised Kudzu preparations commercially available.

---

Evidence for Puerarin Applications

Cardiovascular (High pharmaceutical evidence): Puerarin IV (50–500 mg/day, 14–28 day hospital courses) has been evaluated in multiple Chinese RCTs for acute coronary syndrome, unstable angina, and heart failure — demonstrating improved cardiac function, reduced troponin release, and enhanced microcirculatory flow. The mechanism involves: cAMP elevation via adenosine receptor agonism (vasodilation); eNOS activation (NO production); platelet aggregation inhibition; and anti-inflammatory reduction of myocardial inflammatory infiltrate. CFDA pharmaceutical approval validates the clinical evidence level. Claim strength: High (IV pharmaceutical); Moderate (oral supplement).

Cerebrovascular and neuroprotective: Puerarin improves cerebral blood flow, reduces glutamate-induced neurotoxicity, and demonstrates neuroprotection in rodent ischaemia models at 25–100 mg/kg. The combination of beta-adrenoceptor antagonism (reducing cardiac oxygen demand), vasodilation, and antioxidant neuroprotection makes puerarin pharmacologically relevant to both cardiac and cerebrovascular ischaemia. Puerarin injection is used in Chinese hospitals for ischaemic stroke supportive treatment. Claim strength: Moderate (oral); High (IV clinical use).

Alcohol metabolism modulation: Puerarin, alongside daidzin in Kudzu root, contributes to the preparation's ability to reduce voluntary alcohol consumption in human RCTs (Lukas 2013, Penetar et al. 2012). The mechanism involves dopaminergic and serotonergic pathway modulation in reward circuits, distinct from daidzin's ALDH2 inhibition. Puerarin's C-glycoside stability ensures it reaches the bloodstream intact (unlike daidzin which is hydrolysed to daidzein), potentially delivering more consistent pharmacological exposure. Claim strength: Moderate.

Menopausal and phytoestrogenic: Puerarin binds ERβ with modest affinity — lower than daidzein but sufficient to contribute to Kudzu root's phytoestrogenic clinical activity. Pueraria mirifica (White Kwao Krua), a Thai species with particularly high puerarin concentrations alongside miroestrol, is studied specifically for menopausal and bone health applications in Southeast Asian RCTs. Claim strength: Moderate.

---

Dosage & Formulator Specification

Pharmaceutical IV dosing for cardiovascular applications is 200–500 mg puerarin/day in Chinese hospital protocols. For oral supplement applications — where puerarin's bioavailability is substantially lower than IV — effective doses are not well-established. Kudzu root RCTs for alcohol consumption used standardised Kudzu extract providing 25–100 mg puerarin equivalent per dose, taken before drinking occasions. General cardiovascular and neuroprotective supplementation typically uses 200–500 mg puerarin-standardised extract per serving.

Herbuno's Puerarin 98% Powder enables precise high-purity oral puerarin formulation — the most concentrated commercially available Kudzu isoflavone preparation. Puerarin 40% Powder (standardised extract) co-delivers puerarin with daidzin, daidzein, and other Kudzu polyphenols for broad-spectrum Kudzu root activity. For alcohol metabolism applications, the 40% extract capturing both puerarin and daidzin is pharmacologically appropriate; for cardiovascular precision dosing, Puerarin 98% is preferred.

Puerarin's C-glycoside bond is stable to acid hydrolysis (gastric pH), alkali, and most gut glucosidases — it reaches the bloodstream as the intact C-glucoside unlike O-glucosides that require enzymatic deglycosylation. Oral bioavailability of puerarin from Kudzu extract is estimated at 10–25% — substantially higher than EGCG or most O-glycoside flavonoids. No phospholipid complexation is required for acceptable bioavailability; microencapsulation improves dissolution for powder sachet and beverage applications.

No clinically significant drug interactions are documented for oral puerarin at supplement doses. At pharmaceutical IV doses, puerarin's vasodilatory and antiplatelet effects require monitoring with anticoagulant and antihypertensive co-medications. Kudzu preparations (containing both puerarin and daidzin) carry the alcohol metabolism interaction noted for daidzin.

---

Frequently Asked Questions — Puerarin

What makes puerarin a C-glucoside and why is this pharmacologically important?
Most flavonoid glycosides are O-glycosides — the sugar is attached via an oxygen bridge (C-O-C) that is cleaved by gut glucosidases and gastric acid, releasing the aglycone. Puerarin's glucose is attached via a direct C-C bond at C-8 of the isoflavone — this C-glycosidic bond is not cleaved by standard digestive enzymes or gastric acid. Puerarin therefore reaches the bloodstream largely intact as the full C-glucoside, distributes systemically, and is excreted or metabolised without losing the glucose unit. This stability gives puerarin distinct pharmacokinetics (longer half-life, more consistent systemic exposure) versus daidzin's O-glucoside.

Is the Kudzu used for supplements the same species used in Chinese medicine?
Chinese medicine uses primarily Pueraria lobata (Ge Gen) — the same species standardised in Herbuno's Puerarin preparations. Indian Kudzu (Pueraria tuberosa, Vidari Kanda in Ayurveda) is a related species with distinct but overlapping isoflavone content used in Ayurvedic medicine for nutritive and reproductive applications. Thai Kwao Krua Khao (Pueraria mirifica) is a Southeast Asian species with unusually high concentrations of miroestrol and deoxymiroestrol — more potent phytoestrogens not present in P. lobata — used specifically for menopausal applications in Thai traditional medicine and Southeast Asian RCTs. Species selection is pharmacologically significant; P. lobata/puerarin is the cardiovascular and alcohol-metabolism evidence-based species.

What is the CFDA approval status of puerarin injection in China?
Puerarin Injection (静脉注射用葛根素) is registered with the China Food and Drug Administration (now NMPA) as a Class II traditional Chinese medicine injection product, used in Chinese hospitals for cardiovascular and cerebrovascular supportive treatment. It has undergone Phase III RCTs in China — although Chinese clinical trial methodology has evolved significantly and earlier trials may not fully meet current international RCT standards. The pharmaceutical approval represents the highest level of regulatory clinical validation for any isoflavone compound globally, even acknowledging these methodological considerations.

How does puerarin from Kudzu compare to puerarin from Pueraria mirifica?
Puerarin is present in both species — the molecular compound is identical. Pueraria mirifica contains puerarin alongside much higher concentrations of miroestrol, deoxymiroestrol, and other coumestans not present in P. lobata. The Thai Kwao Krua Khao (P. mirifica) preparations are positioned primarily for phytoestrogenic and menopausal applications, with puerarin as one of multiple active constituents. P. lobata preparations are positioned for cardiovascular, neuroprotective, and alcohol metabolism applications with puerarin as the primary bioactive. Herbuno's puerarin products are P. lobata-derived.

Related compounds: Daidzin, Daidzein, Calycosin, Wedelolactone

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery